Intellia Therapeutics (NTLA) AI Stock Analysis

• Market Cap: $986.87M
• Dividend Yield: N/A
• Average Volume (3M): 9.61M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.23
• Revenue Growth: 33.52%
• EPS Growth: 21.66%
• Country: US
• Employees: 403
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.92
• Shares Outstanding: 115,829,926
• 10 Day Avg. Volume: 5,983,040
• 30 Day Avg. Volume: 9,610,986
• PEG Ratio: 0.71
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 19.91
• P/FCF Ratio: -3.25
• Enterprise Value/Market Cap: 1.51
• Enterprise Value/Revenue: 25.90
• Enterprise Value/Gross Profit: -69.55
• Enterprise Value/Ebitda: -3.27
• 1Y Price Target: $15.97
• Price Target Upside: 87.44% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 22
• EPS Forecast (FY): -4.03
• Revenue Forecast (FY): $56.54M

• Rating: 40 Underperform
• Price Target: $8.00 ▼(-6.10% Downside)

Intellia Therapeutics faces significant challenges with its financial performance and technical indicators, both scoring at the lower end due to ongoing losses, negative cash flows, and bearish market sentiment. The earnings call highlighted both progress in certain programs and serious setbacks, particularly the clinical hold on key trials, which negatively impacts the outlook. The valuation remains unattractive due to negative earnings and lack of dividends, typical for a biotech in its development phase.

Positive Factors

Strong Cash Position

A robust cash position provides financial stability and flexibility, allowing Intellia to continue investing in its pipeline and operations, supporting long-term growth.

Collaboration Revenue Growth

Growing collaboration revenue indicates successful partnerships and potential for sustained income, enhancing financial stability and resource sharing for development.

Pipeline Progress

Completion of enrollment in key trials signifies progress in the pipeline, potentially leading to new product launches and revenue streams, strengthening market position.

Negative Factors

Clinical Hold on Trials

Clinical holds can delay product development and commercialization, impacting revenue timelines and increasing uncertainty in achieving strategic milestones.

Declining Shareholder Equity

Declining shareholder equity reflects financial strain and potential erosion of investor confidence, which can affect the company's ability to raise capital and invest in growth.

Negative Free Cash Flow

Consistently negative free cash flow indicates cash burn, which can limit operational flexibility and necessitate external funding, posing risks to financial sustainability.

Intellia Therapeutics Business Overview & Revenue Model

Company Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Intellia Therapeutics generates revenue through several key streams. Primarily, the company earns money by developing and advancing its therapeutic candidates through clinical trials and subsequently partnering with larger pharmaceutical companies for commercialization. These partnerships often involve upfront payments, research funding, and milestone payments based on the achievement of specific development goals. Additionally, Intellia may receive royalties on sales of products that emerge from these collaborations. The company also benefits from government grants and research funding aimed at advancing gene-editing technologies. Significant partnerships with major firms in the pharmaceutical industry further contribute to Intellia's revenue model, providing financial support and shared resources for the development of its therapies.

Intellia Therapeutics Financial Statement Overview

Summary

Intellia Therapeutics is experiencing typical financial challenges for a biotech firm in its growth phase, with high R&D expenses leading to net losses and negative cash flows. The balance sheet shows adequate cash reserves, but declining shareholder equity and zero revenue in 2024 highlight significant risks in future revenue generation and profitability.

Income Statement

Intellia Therapeutics has faced a challenging financial environment, with declining revenues from $57.99 million in 2020 to $36.27 million in 2023, and ultimately to zero in 2024. The company has consistently incurred net losses, with a significant net loss of $519.02 million in 2024, indicating high operational costs and low revenue, characteristic of a biotech firm in early stages of development.

Balance Sheet

The balance sheet shows adequate cash reserves with $601.52 million in cash and equivalents. However, the debt-to-equity ratio stands at 0.24, indicating manageable leverage, but the persistent decrease in stockholders' equity from $1.05 billion in 2023 to $871.96 million in 2024 suggests a deterioration in shareholder value. The equity ratio is relatively stable, providing a moderate level of financial stability.

Cash Flow

The cash flow statement highlights negative free cash flow each year, with a free cash flow of -$408.07 million in 2024, driven by high operating cash outflows. The operating cash flow to net income ratio is unfavorable due to consistent losses, signaling inefficiencies in cash generation relative to expenses. This is typical for a biotech firm still in development phases.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	57.53M	57.88M	36.27M	52.12M	33.05M	57.99M
Gross Profit	-21.42M	47.59M	27.30M	44.55M	26.16M	-92.41M
EBITDA	-456.10M	-523.98M	-506.31M	-450.59M	-260.96M	-130.27M
Net Income	-445.81M	-519.02M	-481.19M	-474.19M	-267.89M	-134.23M
Balance Sheet
Total Assets	925.27M	1.19B	1.30B	1.52B	1.29B	676.32M
Cash, Cash Equivalents and Short-Term Investments	511.04M	601.51M	912.22M	1.19B	748.69M	597.37M
Total Debt	97.97M	210.20M	115.35M	130.70M	74.02M	39.30M
Total Liabilities	176.85M	319.06M	250.81M	284.53M	254.22M	149.25M
Stockholders Equity	748.42M	871.96M	1.05B	1.24B	1.04B	527.07M
Cash Flow
Free Cash Flow	-412.63M	-354.66M	-408.07M	-391.68M	-237.79M	-53.50M
Operating Cash Flow	-410.65M	-348.88M	-394.09M	-333.29M	-225.03M	-49.91M
Investing Cash Flow	352.06M	125.57M	-31.35M	160.31M	-550.78M	-214.49M
Financing Cash Flow	131.83M	185.75M	130.32M	582.96M	736.69M	371.78M

Intellia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Negative. The current price of 8.52 is below the 20-day moving average (MA) of 9.96, below the 50-day MA of 16.42, and below the 200-day MA of 11.45, indicating a bearish trend. The MACD of -2.45 indicates Negative momentum. The RSI at 32.11 is Neutral, neither overbought nor oversold. The STOCH value of 38.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NTLA.

Intellia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XNCR	57 Neutral	$1.02B	-7.88	-19.61%	―	38.16%	48.43%
ARVN	56 Neutral	$797.67M	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VIR	51 Neutral	$895.97M	―	-49.06%	―	-78.55%	7.74%
NRIX	51 Neutral	$1.72B	―	-65.35%	―	48.32%	-1.91%
NTLA	40 Underperform	$986.87M	―	-52.11%	―	33.52%	21.66%
RCKT	40 Underperform	$356.05M	-1.46	-74.88%	―	―	18.39%

Intellia Therapeutics Corporate Events

Intellia Therapeutics Reports Q3 2025 Financial Results

Intellia Therapeutics, Inc. is a clinical-stage gene editing company leveraging CRISPR-based therapies to develop innovative treatments for unmet medical needs, primarily in the biotechnology sector.

Intellia Reports Favorable Phase 1 Data for Nex-Z

On November 8, 2025, Intellia Therapeutics announced positive results from its Phase 1/2 trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema, showing significant reductions in plasma kallikrein and a favorable safety profile. The trial results, presented at a scientific meeting, suggest lonvo-z could become a one-time treatment option, with a Phase 3 trial ongoing. On November 10, 2025, Intellia also reported favorable Phase 1 data for nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with cardiomyopathy, demonstrating sustained serum TTR reduction and disease stabilization. However, the FDA placed a clinical hold on the Phase 3 trials for nex-z, impacting its development timeline.

The most recent analyst rating on (NTLA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Therapeutics’ Earnings Call: Progress Amid Challenges

Intellia Therapeutics Inc. recently conducted its earnings call, revealing a blend of progress and challenges. The company has made significant strides in its lonvo-z program and maintained financial stability. However, the clinical hold on nex-z trials due to patient safety concerns has notably impacted the company’s outlook. The sentiment of the call was heavily influenced by the serious nature of these clinical holds and the associated patient safety issues.

Intellia Therapeutics Faces FDA Clinical Hold on Trials

On October 29, 2025, Intellia Therapeutics was informed by the FDA of a clinical hold on their Phase 3 trials for nexiguran ziclumeran due to safety concerns. The hold follows reports of severe liver issues in a patient, prompting the company to pause the trials and work with the FDA to resolve the matter.

The most recent analyst rating on (NTLA) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Therapeutics’ Long-Term Study of NTLA-2001: What Investors Need to Know

Intellia Therapeutics Inc. is conducting a long-term follow-up study titled Long-Term Follow-Up of Subjects Treated With NTLA-2001. The study aims to observe the long-term effects of NTLA-2001, an investigational therapy, on subjects who participated in a previous trial. This research is significant as it evaluates the sustained impact of NTLA-2001 on conditions like Transthyretin-Related Familial Amyloid Polyneuropathy and Cardiomyopathy, as well as Wild-Type Transthyretin Cardiac Amyloidosis.

Intellia’s NTLA-2002: A Promising Long-Term Study Update

Intellia Therapeutics Inc. is conducting a study titled ‘Long-Term Follow-Up of Subjects Treated With NTLA 2002,’ focusing on the long-term effects of NTLA-2002, an investigational therapy for Hereditary Angioedema. The study aims to observe the outcomes of patients who previously received NTLA-2002, providing valuable insights into the therapy’s extended impact.

Intellia Therapeutics Pauses Phase 3 Trials Due to Safety Concerns

On October 27, 2025, Intellia Therapeutics announced a temporary pause in dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nexiguran ziclumeran (nex-z) due to a report of severe liver issues in a patient. This decision affects trials for transthyretin amyloidosis with cardiomyopathy and polyneuropathy, involving over 650 and 47 patients respectively. The company is consulting with experts and regulatory authorities to address the safety concerns and strategize resuming the trials, highlighting its commitment to patient safety and regulatory compliance.

The most recent analyst rating on (NTLA) stock is a Hold with a $29.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Therapeutics Announces Positive Phase 1 Trial Results

On September 25, 2025, Intellia Therapeutics announced positive longer-term data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary transthyretin amyloidosis with polyneuropathy. The trial showed deep, durable TTR reductions and favorable safety data, with most patients experiencing stability or improvement in clinical measures. The company is advancing its Phase 3 MAGNITUDE-2 trial, with completion of enrollment expected in the first half of 2026, and plans to submit a biologics license application by 2028.

The most recent analyst rating on (NTLA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer?

Study Overview: Regeneron Pharmaceuticals and Intellia Therapeutics are conducting a study titled A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B. The study aims to evaluate the safety and effectiveness of a gene insertion therapy for individuals with hemophilia B, a condition caused by a genetic mutation in the coagulation Factor 9 gene. The primary goal is to determine a safe and well-tolerated dose of the therapy, with secondary objectives including the assessment of drug presence in the blood, antibody formation, and the impact on quality of life and joint health.